Ukrianian court puts on hold lawsuit against ban on Russian social networksWorld May 28, 6:10
Russia’s Lasitskene wins high jump in Diamond League event in Eugene, USSport May 28, 4:59
Havana Airport gets Russian-made air traffic control systemsWorld May 28, 4:16
Guests of FIFA 2018 World Cup sure to get warm welcome in Russia — LavrovSport May 28, 2:25
Kantemir Balagov’s "Closeness" gets Cannes Festival’s International Critics’ PrizeSociety & Culture May 28, 1:03
Anti-church laws in Ukraine may cause religious strife — Ukrainian Orthodox ChurchWorld May 28, 0:22
Russia’s national football team absolutely clear of doping — doctorSport May 28, 0:14
Russian cyclist Zakarin finishes second in Giro d’Italia Stage 20Sport May 27, 22:27
Putin, Erdogan agree to develop coordination of efforts for settlement in SyriaRussian Politics & Diplomacy May 27, 19:29
DARMSTADT, Germany, May 15, 2017 /PRNewswire/. Merck, a leading science and technology company, today took a significant step toward increasing manufacturing flexibility and enabling higher productivity with the launch of the EX-CELL® Advanced™ HD Perfusion Medium. This first off-the-shelf, high-density cell culture media supports perfusion processes at low perfusion rates, increasing production yield and speed to clinic.
Biomanufacturers are moving toward perfusion processes, the next generation in manufacturing, as they seek to cut costs while increasing quality and efficiency. Perfusion processes, however, require a new type of medium. Merck's EX-CELL® Advanced™ HD Perfusion Medium meets "next-gen" manufacturing requirements, allowing customers to achieve a more optimal output than they would using conventional batch or fed-batch processes.
"This launch is a major milestone on the road to truly enabling next generation processing," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "The benefits of perfusion technology include increased cost efficiency, decreased risk and enhanced manufacturing flexibility—ultimately advancing our customers' production capabilities and increasing access to therapies for people worldwide."
A benefit of perfusion processing is higher protein yields, compared with fed-batch, which has been the primary mammalian cell cultivation mode for biopharma manufacturing over the past few decades. Perfusion technology is compatible with small portable plants and can be used with many drug types over a range of production scales.
Merck's EX-CELL® Advanced™ HD Perfusion Medium is the most recent addition to the company's EX-CELL® Advanced™ product line, which offers increased performance, streamlines regulatory compliance and provides the supply chain security needed in today's evolving biopharmaceutical environment.
All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Info - https://mma.prnewswire.com/media/511597/Merck_Next_Gen_Stats_Infographic.jpg
Photo - http://mma.prnewswire.com/media/511424/Perfusion.jpg
CONTACT: Karen Tiano +49 6151 72 44461